Shares of GenMark Diagnostics (GNMK -25%) get slammed after one of its customers, Natural Molecular Testing, launches their laboratory developed comprehensive Personalized Medicine Panel using Luminex's (LMNX +6%) xMAP technology. Terms of the multi-year collaboration and license agreement were not disclosed.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs